Skip to content

BOSTON DR LIM

  • 보스턴임박사
  • 보스턴임박사 브런치
  • 커리어 코칭
  • 가지않은길:mRNA백신연구원
  • 바이오테크
  • 보스턴 일상
  • 자유와 이유
  • 버킷리스트
  • 벤처의 역사

BIOTECH (93) – RAPT Therapeutics: Zelnecirnon (RPT193, CCR4 Inhibitor) got Clinical Hold

February 20, 2024February 20, 2024

BIOTECH (92) – Vertex Non-Opioid Replacement NaV1.8 Inhibitor Suzetrigine (VX-548) Phase 3

February 20, 2024February 20, 2024

BIOTECH (91) – Replicate Bioscience: Self-Replicating mRNA against Therapy-Acquired Neoantigen

February 19, 2024

부러우면 지는거다 (25) – Victor Gonzalez: Chemist with Art Pigments Analysis

February 19, 2024February 19, 2024

BIOTECH (90) – Iovance Biotherapeutics: FDA Accelerated Approval of lifileucel (Amtagvi), the first Tumour-Infiltrating Lymphocyte (TIL) Cancer Therapy

February 19, 2024

내가 쓰는 나의 삶 (34) – 미래에셋 투자와 연금센터: 투자와 연금 11호 퇴직전 준비하지 못해 후회하는 것들

February 19, 2024February 19, 2024

내가 쓰는 나의 삶 (33) – 日 베스트셀러 ‘진짜 정년후’ 사카모토씨 인터뷰

February 19, 2024October 16, 2025

BIOTECH (89) Cymabay Therapeutics: Seladelpar, an oral, selective peroxisome proliferator-activated receptor delta (PPARδ) agonist

February 18, 2024February 19, 2024

BIOTECH (88) – Recode Therapeutics: SORT LNP Delivery Platform Beyond Liver

February 18, 2024

BIOTECH (87) – Gilead’s Magrolimab (Hu5F9-G4) CD47-SIRPα blocker with Azacitidine for AML Phase 3 ENHANCE Study Terminated & Solid Tumor Partial Clinical Hold

February 18, 2024

Posts navigation

Older posts
Newer posts
Website Powered by WordPress.com.
  • Subscribe Subscribed
    • BOSTON DR LIM
    • Already have a WordPress.com account? Log in now.
    • BOSTON DR LIM
    • Subscribe Subscribed
    • Sign up
    • Log in
    • Report this content
    • View site in Reader
    • Manage subscriptions
    • Collapse this bar
 

Loading Comments...